Table 4. The comparison of the associated factors and cognitive impairment among patients without OH and with non-neurogenic or neurogenic OH.
| No OH | Non-neurogenic OH | Neurogenic OH | P value | |
|---|---|---|---|---|
| N = 143 | 65 | 38 | 40 | |
| Age | 61.5±11.4 | 61.7±9.8 | 69.3±7.1a | <0.001 |
| Disease duration | 9.8±4.9 | 12.2±8.5 | 11.4±6.8 | NS |
| H-Y | 2.8±0.8 | 2.6±0.8 | 3.4±0.8a | <0.001 |
| Education (y) | 13.6±2.5 | 13.2±2.4 | 13.2±2.4 | NS |
| HT | 16 (24.6%) | 4 (10.5%) | 12 (30.0%) | NS |
| SH | 3 (4.6%) | 4 (10.5%) | 15 (37.5%) | <0.0001 |
| DWMH | 0.68±0.69 | 0.70±0.70 | 0.92±0.81 | NS |
| LED | 907.6±371.5 | 1013.0±346.6 | 981.6±425.6 | NS |
| Beta-blocker | 3 (4.6%) | 0 | 1 (2.5%) | NS |
| Dementia | 4 (6.2%) | 6 (15.8%) | 13 (32.5%) | <0.01 |
| HDS-R | 27.5±3.7 | 26.6±4.4 | 25.2±4.9a | <0.05 |
| MMSE | 28.1±2.8 | 27.4±3.0 | 25.7±4.1a | <0.01 |
| MoCA | 25.2±4.3 | 24.8±4.0 | 21.9±5.3a | <0.01 |
| ΔSBP | -2.0±11.0 | -31.3±14.9a | -31.5±21.2a | <0.001 |
| ΔDBP | 3.8±7.0 | -15.7±9.1a | -17.8±10.7a | <0.001 |
a significant differences compare to no OH groups.